Cite
HARVARD Citation
Lewis, K. et al. (n.d.). 428 Interim analysis of Phase 2 results for cemiplimab in patients with metastatic basal cell carcinoma (mBCC) who progressed on or are intolerant to hedgehog inhibitors (HHIs). Journal for immunotherapy of cancer. pp. A260-A261. [Online].